Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Journal: J Med Econ

Volume: 

Issue: 

Year of Publication: 2024

Affiliated Institutions: 

Abstract summary 

Authors & Co-authors: 

Study Outcome 

Source Link: Visit source

Statistics
Citations :  2
Authors :  0
Identifiers
Doi : 10.1080/13696998.2023.2293379
SSN : 
Study Population
Male,Female
Mesh Terms
Other Terms
Study Design
Study Approach
Country of Study
Tunisia
Publication Country